Computational study reveals substituted benzimidazole derivatives’ binding selectivity to PI3Kδ and PI3Kγ

[1] Cantley L(2002)The phosphoinositide 3-kinase pathway Science 296 1655-1657

[2] Leevers SJ(1999)Signalling through phosphoinositide 3-kinases: the lipids take centre stage Curr Opin Cell Biol 11 219-225

[3] Vanhaesebroeck B(2004)PI3K/Akt signalling pathway and cancer Cancer Treat Rev 30 193-204

[4] Fresno Vara JA(2008)PI3K pathway alterations in cancer: variations on a theme Oncogene 27 5497-5510

[5] Casado E(2002)The phosphatidylinositol 3-kinase AKT pathway in human cancer Nat Rev Cancer 2 489-501

[6] De-Castro J(2012)Antithrombotic phosphoinositide 3-kinase β inhibitors in humans: a ‘shear’ delight! J Thromb Haemost 10 2123-2126

[7] Yuan TL(2017)Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow Expert Rev Anticancer Ther 17 271-279

[8] Cantley LC(2011)Present and future of PI3K pathway inhibition in cancer: perspectives and limitations Curr Med Chem 18 2674-2685

[9] Vivanco I(2009)Inhibitors of phosphoinositide-3-kinase: a structure-based approach to understanding potency and selectivity Organic & Biomolecular Chemistry 7 840-850

[10] Sawyers CL(2020)Ex vivo blockade of PI3K gamma or delta signaling enhances the antitumor potency of adoptively transferred CD8+ T cells Eur J Immunol 50 1386-1399

[1] Cantley L(2002)The phosphoinositide 3-kinase pathway Science 296 1655-1657

[2] Leevers SJ(1999)Signalling through phosphoinositide 3-kinases: the lipids take centre stage Curr Opin Cell Biol 11 219-225

[3] Vanhaesebroeck B(2004)PI3K/Akt signalling pathway and cancer Cancer Treat Rev 30 193-204

[4] Fresno Vara JA(2008)PI3K pathway alterations in cancer: variations on a theme Oncogene 27 5497-5510

[5] Casado E(2002)The phosphatidylinositol 3-kinase AKT pathway in human cancer Nat Rev Cancer 2 489-501

[6] De-Castro J(2012)Antithrombotic phosphoinositide 3-kinase β inhibitors in humans: a ‘shear’ delight! J Thromb Haemost 10 2123-2126

[7] Yuan TL(2017)Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow Expert Rev Anticancer Ther 17 271-279

[8] Cantley LC(2011)Present and future of PI3K pathway inhibition in cancer: perspectives and limitations Curr Med Chem 18 2674-2685

[9] Vivanco I(2009)Inhibitors of phosphoinositide-3-kinase: a structure-based approach to understanding potency and selectivity Organic & Biomolecular Chemistry 7 840-850

[10] Sawyers CL(2020)Ex vivo blockade of PI3K gamma or delta signaling enhances the antitumor potency of adoptively transferred CD8+ T cells Eur J Immunol 50 1386-1399